Background Most low-income and middle-income countries (LMICs) have little or no data
integrated into a national surveillance system to identify characteristics or outcomes of COVID-…

Objective To estimate the effectiveness of the inactivated whole virus vaccine, CoronaVac (Sinovac
Biotech), against symptomatic covid-19 in the elderly population of São Paulo state, …

Community-acquired pneumonia causes great mortality and morbidity and high costs worldwide.
Empirical selection of antibiotic treatment is the cornerstone of management of patients …

Introduction Residual inflammation at ICU discharge may have impact upon long-term
mortality. However, the significance of ongoing inflammation on mortality after ICU discharge is …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant,
Gamma, emerged in the city of Manaus in late 2020 during a large resurgence of coronavirus …

The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19
caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study …

The accuracy of the signs and tests that clinicians use to diagnose ventilator-associated
pneumonia (VAP) and initiate antibiotic treatment has not been well characterized. We sought to …

Rationale: The Sepsis-3 Task Force updated the clinical criteria for sepsis, excluding the
need for systemic inflammatory response syndrome (SIRS) criteria. The clinical implications of …

Rationale: To identify pathogens that require different treatments in community-acquired
pneumonia (CAP), we propose an acronym, “PES” (Pseudomonas aeruginosa, …

A two-dose regimen of the Oxford-AstraZeneca (ChAdOx1) Covid-19 vaccine with an inter-dose
interval of three months has been implemented in many countries with restricted vaccine …